Form 4: Amicus Therapeutics CFO Reports Exit Following Merger

Amicus Therapeutics CFO Simon N.R. Harford reports the disposal of all equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.

Summary

• Simon N.R. Harford, Chief Financial Officer of Amicus Therapeutics, reported the disposal of 143,595 shares of common stock.
• The transaction occurred on April 27, 2026, at a price of $14.50 per share.
• The disposal was executed in connection with the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
• Multiple tranches of stock options were cancelled and converted into cash payments based on the $14.50 per share merger price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final exit of an executive following a completed corporate acquisition.

Positives

• The transaction confirms the successful completion of the merger with BioMarin Pharmaceutical Inc. at a set price of $14.50 per share.

Negatives

• The reporting person has liquidated their entire equity position in the company.

Risks

• No ongoing risks as the company has been acquired and the reporting person has exited their position.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc.; therefore, no further independent forward-looking guidance is provided by the issuer.

Management Comments

• The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc.

Industry Context

StockSavvy.ai notes that this filing marks the final administrative step for executive equity holdings following a significant M&A event in the biopharmaceutical sector, signaling the integration of Amicus Therapeutics into BioMarin.

Comparison to Industry Standards

• The $14.50 acquisition price represents the final valuation benchmark for the company's equity holders.
• The full vesting of restricted stock units and options upon a change-in-control event is standard practice in executive compensation agreements within the biotech industry.

Stakeholder Impact

• Shareholders have received the merger consideration of $14.50 per share.

Next Steps

• Delisting of Amicus Therapeutics (FOLD) from public exchanges following the merger completion.

Key Dates

Keywords

Amicus Therapeutics, FOLD, BioMarin Pharmaceutical, Merger, CFO, Insider Transaction, Form 4